There is growing evidence that GEC is enriched with several actionable targets including HER2, mismatch repair deficiency, PD-L1 expression, as well as emerging targets such as Claudin 18.2 and FGFR2b.17,40-43 Many of these pivotal trials had very few “older-old” patients; however, these results are likely to be extrapolated in clinical practice. Here, CD274 is linked to mismatch repair cancer syndrome 1.